U.S. Court Declines A Review Of Drug Patent Deals

NEW YORK - A U.S. Appeals Court on Tuesday declined to consider a deeper legal review of patent settlements by drug companies that pay rivals to delay production of generic drugs, setting the stage for the Supreme Court or Congress to address the matter.